Kensey Nash acquires assets of Nerites

Kensey Nash (NASDAQ:KNSY) has acquired the assets of closely held Nerites Corp., a developer of medical adhesives and anti-fouling coatings based in Madison, WI. for $20 million in cash. Nerites is developing a technology platform of adhesive-based biomaterials, which would allow Kensey Nash to further its penetration into the regenerative medicine markets, encompassing soft tissue [...]

Masimo and Covidien extend royalty pact

Masimo (NASDAQ;MASI) and Covidien (NYSE: COV) have amended an existing settlement agreement initially reached in January 2006. Under the terms of the amendment, Covidien will pay Masimo a royalty of 7.75% for its current pulse oximetry products sold in the U.S. for three years, beginning March 15, 2011. Shares of Masimo jumped 10% in early [...]

Angiotech files for bankruptcy protection under CCAA

The board of Angiotech Pharmaceuticals (TSX:ANP) has authorized the company and certain subsidiaries to voluntarily file under the Companies’ Creditors Arrangement Act (CCAA) in order to continue implementation of its previously announced recapitalization transaction. The proposed recapitalization would involve the elimination of Angiotech’s $250 million 7.75% senior subordinated notes and obligations in order to improve [...]

Paladin gets Health Canada approval for DigiFab

Paladin Labs (TSX:PLB) has received approval from Health Canada to market DigiFab for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. Digoxin, which is also known as digitalis, is used to treat congestive heart failure and to slow heart rate in some cardiac disturbances. Paladin acquired the exclusive Canadian rights [...]

National starts Ventrus at buy

National Securities initiated coverage of Ventrus BioSciences (NASDAQ:VTUS) with a “buy,” saying the company has two late-stage therapeutics that can “transform the treatment paradigm in anal fissures and hemorrhoids, and an earlier stage therapeutic that has potential in fecal incontinence.” Analyst Jason Kolbert writes that with Ventrus’ market capitalization of just over $40 million, “we [...]

ThermoGenesis, TotipotentSC cleared for Phase 1b trial

ThermoGenesis (Nasdaq: KOOL) and TotipotentSC have received approval from Fortis Escorts’ (New Delhi) Independent Ethics Committee to proceed with a Phase 1b clinical trial in patients suffering from non-reconstructable critical limb ischemia (CLI) utilizing ThermoGenesis’ Res-Q 60 BMC system. The objectives of the trial are to assess safety and efficacy of stem cells derived from [...]

Canaccord ups Heartware; cuts Thoratec

In a new report about the left ventricular assist device (LVAD) market, Canaccord Genuity has raised its 12-month price target for Heartware (NASDAQ:HTWR) to $115 from $98 and lowered its target for Thoratec (NASDAQ:THOR) to $32 from $43. “We prefer Heartware long-term but believe Thoratec common represents a favorable risk/reward investment at current levels,” writes [...]

Diamedica to test influenza program in animals

Diamedica (TSX-V:DMA) has entered into an evaluation agreement with the NIH’s National Institute of Allergy and Infectious Diseases to further test its monoclonal antibody (mAb) program  against influenza infection in animal models. Diamedica’s mAb previously was able to dose dependently and prevent influenza replication in an in vitro host cell model. “The company believes that [...]

INVO begins clinical trial in Brazil

INVO Bioscience (OTCBB:IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, has begun a 40-patient clinical trial in Rio de Janeiro to establish safety, efficacy and comparative in-vitro fertilization measures of its INVOcell device. The first trial patient has been treated utilizing the INVOcell device and procedure. An ultrasound exam [...]

Nordion in cobalt-60 supply pact

Nordion (NYSE:NDZ; TSX:NDN) has signed a five-year contract with Sterigenics International, a leader in contract sterilization and ionization services, for the supply of cobalt-60. “This contract provides for growth, further demonstrates the attractiveness of this core business, and builds on our global market leadership position,” CEO Steve West said in a statement.  “We continue to drive [...]

Next Page »